BRAF and melanoma: To mimic the clinical scenario of patient relapse from targeted therapy, we also used BRAF- and MEK-inhibitor treated melanoma cell lines, resistant up to doses of 5 μM and 200 μM, respectively (Supplementary Fig. 7a).